Allosterism and cannabinoid CB1 receptors

the shape of things to come

Ruth A. Ross

Research output: Contribution to journalLiterature review

66 Citations (Scopus)

Abstract

In 2005, the first evidence was obtained that the cannabinoid CB, receptor contains an allosteric binding site. The site can be recognized by synthetic small molecules, which display a markedly divergent effect on orthosteric ligand affinity versus efficacy; these small molecules are allosteric enhancers of agonist binding affinity and allosteric inhibitors of agonist signalling efficacy. Allosteric modulation heralds a new approach to the manipulation of the endocannabinoid system for therapeutic benefit; it promises to augment the existing portfolio of selective direct agonists, competitive antagonists and enzyme inhibitors.

Original languageEnglish
Pages (from-to)567-572
Number of pages6
JournalTrends in Pharmacological Sciences
Volume28
DOIs
Publication statusPublished - 2007

Keywords

  • protein-coupled receptors
  • endocannabinoid system
  • multiple-sclerosis
  • neutral antagonism
  • inverse agonism
  • bone mass
  • exploitation
  • inflammation
  • ligands
  • pain

Cite this

Allosterism and cannabinoid CB1 receptors : the shape of things to come. / Ross, Ruth A.

In: Trends in Pharmacological Sciences, Vol. 28, 2007, p. 567-572.

Research output: Contribution to journalLiterature review

@article{00cd87b9fcc6440cbf8aaf20d654e38c,
title = "Allosterism and cannabinoid CB1 receptors: the shape of things to come",
abstract = "In 2005, the first evidence was obtained that the cannabinoid CB, receptor contains an allosteric binding site. The site can be recognized by synthetic small molecules, which display a markedly divergent effect on orthosteric ligand affinity versus efficacy; these small molecules are allosteric enhancers of agonist binding affinity and allosteric inhibitors of agonist signalling efficacy. Allosteric modulation heralds a new approach to the manipulation of the endocannabinoid system for therapeutic benefit; it promises to augment the existing portfolio of selective direct agonists, competitive antagonists and enzyme inhibitors.",
keywords = "protein-coupled receptors, endocannabinoid system, multiple-sclerosis, neutral antagonism, inverse agonism, bone mass, exploitation, inflammation, ligands, pain",
author = "Ross, {Ruth A.}",
year = "2007",
doi = "10.1016/j.tips.2007.10.006",
language = "English",
volume = "28",
pages = "567--572",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Allosterism and cannabinoid CB1 receptors

T2 - the shape of things to come

AU - Ross, Ruth A.

PY - 2007

Y1 - 2007

N2 - In 2005, the first evidence was obtained that the cannabinoid CB, receptor contains an allosteric binding site. The site can be recognized by synthetic small molecules, which display a markedly divergent effect on orthosteric ligand affinity versus efficacy; these small molecules are allosteric enhancers of agonist binding affinity and allosteric inhibitors of agonist signalling efficacy. Allosteric modulation heralds a new approach to the manipulation of the endocannabinoid system for therapeutic benefit; it promises to augment the existing portfolio of selective direct agonists, competitive antagonists and enzyme inhibitors.

AB - In 2005, the first evidence was obtained that the cannabinoid CB, receptor contains an allosteric binding site. The site can be recognized by synthetic small molecules, which display a markedly divergent effect on orthosteric ligand affinity versus efficacy; these small molecules are allosteric enhancers of agonist binding affinity and allosteric inhibitors of agonist signalling efficacy. Allosteric modulation heralds a new approach to the manipulation of the endocannabinoid system for therapeutic benefit; it promises to augment the existing portfolio of selective direct agonists, competitive antagonists and enzyme inhibitors.

KW - protein-coupled receptors

KW - endocannabinoid system

KW - multiple-sclerosis

KW - neutral antagonism

KW - inverse agonism

KW - bone mass

KW - exploitation

KW - inflammation

KW - ligands

KW - pain

U2 - 10.1016/j.tips.2007.10.006

DO - 10.1016/j.tips.2007.10.006

M3 - Literature review

VL - 28

SP - 567

EP - 572

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

ER -